<DOC>
	<DOCNO>NCT02907307</DOCNO>
	<brief_summary>The purpose study compare efficacy safety LactiSal 1 % vaginal gel LactiSal 50 mg vaginal tablet standart treatment clotrimazole 100 mg vaginal tablet woman vulvovaginal candidiasis ( VVC )</brief_summary>
	<brief_title>Efficacy , Safety LactiSal 1 % Gel , LactSal 50 mg , Clotrimazole 100 mg Tablet Treatment Vulvovaginal Candidiasis</brief_title>
	<detailed_description>National multicenter , randomize , open-label , active-controlled three parallel groups.Eligible patient randomize receive LactiSal 1 % vaginal gel , LactiSal 50 mg vaginal tablet clotrimazole 100 mg vaginal tablet 6 day . Control examaminations perform 10 entry 4 week control visit 1 . The study investigate clinical efficacy safety Lactisal 1 % vaginal gel LactiSal 50mg vaginal tablet intend use , i.e . vaginal application , follow intend claim : - Treatment vaginal yeast vaginitis - Relieves vaginal itching , burning , redness discharge case yeast vaginitis - Inhibition yeast colonization vagina case yeast vaginitis . The study design compare clinical efficacy safety Lactisal 1 % vaginal gel LactiSal 50 mg vaginal tablet current standard drug therapy , i.e . clotrimazole 100 mg vaginal tablet . While LactiSal classify medical device class IIa , comparator medicinal ( pharmaceutical ) product . The study represent `` mixed '' study , compare efficacy medical device pharmaceutical product .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Clotrimazole</mesh_term>
	<criteria>1 . Clinical sign &amp; symptom VVC Total Severity Score , TSC 4 ( range 015 ) : vaginal itching ( range 03 ) , vaginal burning soreness ( range 03 ) , abnormal vaginal discharge ( range 03 ) , vulvo/vaginal erythema oedema ( range 03 ) , vulvar excoriation fissure formation ( range 03 ) . 2 . Direct microscopy ( Wet smear ) positive yeast form ( hypha , pseudohyphae ) budding yeast 3 . Normal vaginal pH ( â‰¤4.5 ) 4 . Age : 18 year old 5 . Signed Written Informed Consent participate study . Recurrent VVC ( 4 episode VVC past 12 month ) . Women vaginal infection , e.g . bacterial vaginosis , aerobic vaginitis , trichomoniasis , mixed infection . Women use oral vaginal antifungal within 2 week prior enrolment . Women use intravaginal product , also vaginal douche contain soap anionic , surfaceactive substance , within 2 week prior enrolment . Women use antibiotic antiinfective within 2 week prior enrolment . Women menstruation bleed enrolment Cervicitis , cervical erosion , malignant tumour genital tract Pregnancy lactation . Women consent sexually abstinent treatment , take oral contraceptive IUD contraception Woman use intravaginal pessary , ring , sponge diaphragms Severe systemic disease ( diabetes mellitus , cancer , tuberculosis , autoimmune disease , severe psychiatric condition , etc. ) . Women confirm suspect STD ( HIV infection , gonorrhoea , syphilis , chlamydiasis , etc. ) . Known suspected hypersensitivity one study medication , inclusive excipients . Participation patient another clinical study concomitantly within 30 day prior enrolment Patient relative , staff directly reporting , investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LactiSal</keyword>
	<keyword>Vaginal therapy</keyword>
</DOC>